Day 0 - Monday, 15th Sept 2025 - ET (Eastern Time, GMT-05:00)
1:30 PM – 1:50 PM: Opening Presentation
Intellectual property and business strategy for life sciences.
- Navigating IP challenges in biotech during economic downturns.
- Legal strategies to protect innovation while optimizing costs.
- Emerging opportunities for biotech companies in a shifting regulatory landscape.
Anita Meiklejohn, Principal, Fish & Richardson
1:50 PM – 2:40 PM: Panel Discussion
Topic: Thriving During Tough Times in Biotech: Fundraising Strategies and Beyond
Discussion Focus:
An in-depth exploration of strategies for biotech companies to succeed during economic and industry downturns.
Key Topics:
- Innovative fundraising strategies to secure capital in a competitive environment.
- Building resilience: operational adjustments and cost optimization during tough times.
- Leveraging partnerships and collaborations to sustain growth.
- Insights into investor priorities and how to align your biotech’s vision with funding opportunities.
- Real-world examples of biotech companies that have successfully weathered challenging periods.
Theresa Heah, CEO, stealth company
John Swart, CEO, Cytotheryx
Audience Engagement:
- Panelists will share actionable advice and lessons learned, followed by a moderated Q&A session to address specific challenges faced by attendees.
2:40 PM – 3:00 PM: Audience Q&A
- Open floor for attendees to ask questions directly to the panelists
- Opportunity to gain tailored advice and clarify insights shared during the session.
- Anita Meiklejohn - Principal, Fish & Richardson
- Theresa Heah - CEO, stealth company
- John Swart - CEO, Cytotheryx
Who Not How: The Secrets of Building World-Class Teams from Inception to Market Dominance
Bringing a MedTech innovation from inception to market dominance requires more than just groundbreaking technology - it demands a world-class team. In this session we’ll explore the principles of “Who Not How” a mindset shift that helps leaders focus on finding the right people instead of shouldering every challenge themselves. We’ll break down the essential components of building a high-performing team, from structuring for success and identifying top talent to crafting competitive compensation packages, ensuring cultural alignment, and optimizing onboarding for long-term retention.
- Why hiring the right team from the start is the #1 success factor in MedTech
- Shifting the mindset from "How do I do this?" to "Who can do this best?"
- Creating the right structure for long-term success
- A comprehensive overview of the recruitment process, identifying the right talent, offering the right compensation, onboarding and vetting
This exclusive leadership forum brings together CEOs from innovative medical technology companies in an intimate setting designed to accelerate industry advancement and foster strategic connections. With a curated group of CEOs, the environment cultivates meaningful dialogue and collaborative problem-solving among industry pioneers.
The intimate setting facilitates in-depth exchanges among leaders in surgical innovations, diagnostic platforms, digital health solutions, and breakthrough medical devices. This creates an environment where lasting partnerships can develop and industry-changing collaborations and practical strategies can be formed.
Join this transformative experience where medtech leaders unite to shape the future of healthcare innovation. The exclusive nature of this forum, with limited attendance, ensures every conversation is meaningful and every connection is valuable.
Connect with fellow innovators who share your passion for advancing healthcare technology and understanding of the unique challenges in bringing life-changing medical solutions to market.
This session is for medtech C-suite executives and senior decision-makers only.
3:30 PM – 4:00 PM: Opening Presentation: Recent Trends in the Deal-Making Landscape and Market Overview
- A comprehensive presentation offering insights into:
- Market trends shaping the pharmaceutical and biotech sectors.
- Regulatory shifts impacting deal-making and partnership strategies.
- Intellectual property (IP) considerations critical to successful collaborations.
- Emerging opportunities for innovation and strategic alliances in the life sciences industry.
Resa Schlossberg, Partner and Head of Intellectual Property and Technology Transactions, Skadden
Maya Florence, Partner, Life Sciences and Health Care; FDA Regulatory; Litigation, Skadden
Faiz Ahmad, Partner, Mergers and Acquisitions, Skadden
4:00 PM – 4:40 PM: Positioning Your Biotech for Strategic Alliances
- Panelists:
- Deepa Talapade, SVP Oncology, Radiology, Business Development & Strategic Alliances, Bayer
- David Fang, Senior Director, Search & Evaluation, AstraZeneca
- Moderator:
- Skadden
An in-depth exploration of how biotech companies can position themselves for successful collaborations with large pharmaceutical firms.
- Common pitfalls in biotech-pharma collaborations and how to avoid them.
- Strategies for effectively communicating your biotech’s value proposition to potential partners.
- Real-world success stories of strategic alliances, highlighting lessons learned and best practices.
4:40 PM – 5:00 PM: Audience Q&A
- Open floor for attendees to ask questions directly to the panelists and Skadden representatives.
- Opportunity to address specific challenges, gain tailored advice, and clarify insights shared during the session.
- Deepa Talpade - SVP Oncology, Radiology, Business Development & Strategic Alliances, Bayer
- David Fang - Senior Director, Search & Evaluation, AstraZeneca
- Faiz Ahmad - Partner, M&A, Skadden
- Resa Schlossberg - Partner and Head of Intellectual Property and Technology Transactions, Skadden
- Maya Florence - Partner, Life Sciences and Health Care; FDA Regulatory; Litigation, Skadden
3:30 PM – 3:50 PM: Opening Presentation
Navigating Fundraising in Biotech in 2025
- Key insights include:
- Current trends and challenges in biotech fundraising.
- Legal and regulatory considerations impacting capital raising efforts.
- Strategies for positioning your biotech company to attract investors in 2025.
- Emerging opportunities in the funding landscape, including global and regional shifts.
Justin Hoffman, Partner, EGS
3:50 PM – 4:40 PM: Panel Discussion
Alternative Sources of Funding and Navigating Fundraising in Biotech
A comprehensive exploration of alternative funding strategies and how biotech companies can successfully navigate the fundraising landscape.
- Areas of funding for biotechs
- Building investor confidence: crafting compelling pitches and aligning with investor priorities.
- Real-world examples of biotech companies that have successfully utilized alternative funding strategies.
Speakers:
Jeff Becker, Managing Director, Avenue Growth Capital
Natalie Torin, Partner, Woods Capital
Justin Hoffman, Partner, EGS
José Navarro-Betancourt, Scientific Director, quadraScope Ventures
4:40 PM – 5:00 PM: Audience Q&A
- Open floor for attendees to ask questions directly to the panelists
- Opportunity to gain tailored advice and clarify insights shared during the session.
- Natalie Torin - Partner, Woods Capital
- Jeff Becker - Managing Director, Avenue Capital
- Justin Grossman - Partner, Elenoff Grossman & Schole
- Jose Navarro - Scientific Director, quadraScope Ventures